Vanda Pharmaceuticals Announces Positive Phase III Results for NEREUS (tradipitant) in GLP-1-Induced Vomiting

Article summary

Vanda Pharmaceuticals reported positive results from its Phase III Study 3601, demonstrating that NEREUS (tradipitant) significantly reduced vomiting episodes in patients receiving GLP-1 receptor agonist therapy.